Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Jagsonpal Pharmaceuticals Ltd. ( (IN:JAGSNPHARM) ).
Jagsonpal Pharmaceuticals Ltd. has received shareholder approval for its proposed buyback of up to 1.6 million equity shares at Rs 250 per share, aggregating up to Rs 40 crore. The move is positioned as a key step in the company’s strategy to optimise its capital structure and enhance long-term shareholder value.
Management highlighted that the buyback is intended to improve capital allocation efficiency, support earnings per share and deliver stronger returns to investors. The endorsement by shareholders underscores confidence in Jagsonpal’s strategic direction, financial discipline and growth outlook, with further details on timelines and record date to be announced in line with regulations.
More about Jagsonpal Pharmaceuticals Ltd.
Jagsonpal Pharmaceuticals Ltd. is a leading Indian pharmaceutical company with more than four decades of presence in the domestic market. It offers a robust portfolio of drugs across gynaecology, orthopaedics, dermatology and child-care, and has built multiple market-leading brands, supported by a pan-India footprint and a sales force of over 1,000 professionals.
Average Trading Volume: 11,878
Technical Sentiment Signal: Buy
Current Market Cap: 13.36B INR
For an in-depth examination of JAGSNPHARM stock, go to TipRanks’ Overview page.